ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.764T>A (p.Ile255Asn) (rs876659675)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000221023 SCV000276382 uncertain significance Hereditary cancer-predisposing syndrome 2015-06-05 criteria provided, single submitter clinical testing The p.I255N variant (also known as c.764T>A), located in coding exon 6 of the TP53 gene, results from a T to A substitution at nucleotide position 764. The isoleucine at codon 255 is replaced by asparagine, an amino acid with dissimilar properties. This alteration has been reported as a somatic mutation 11 times in various tumors, but not as a germline mutation by the IARC TP53 database (Petitjean A et al. IARC TP53 database [version R17, November 2013]. Hum Mutat. 2007 Jun;28(6):622-9).This variant is in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation capacityin yeast based assays (IARC TP53 database; Kato S et al. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9). Based on internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability (ChoY,Science1994 Jul; 265(5170):346-55).This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 125000 alleles tested) in our clinical cohort.This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of p.I255Nremains unclear.
Invitae RCV000633370 SCV000754592 uncertain significance Li-Fraumeni syndrome 2017-12-12 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with asparagine at codon 255 of the TP53 protein (p.Ile255Asn). The isoleucine residue is highly conserved and there is a large physicochemical difference between isoleucine and asparagine. This variant is not present in population databases (ExAC no frequency). This variant has been reported as a somatic variant in individuals affected with acute myeloid leukemia (PMID: 26781615, 26230955), but has not been reported as a germline variant in the literature in individuals with TP53-related disease. ClinVar contains an entry for this variant (Variation ID: 232289). An experimental study in yeast has shown that this variant impairs the transcriptional transactivation activity of the TP53 protein (PMID: 12826609). A single amino acid deletion at this codon (p.Ile255del) has been reported as a de novo variant in an individual affected with breast cancer, and has been determined to be likely pathogenic (Invitae). Although the single amino acid deletion and the missense change may affect the function of the TP53 protein in different ways, this suggests that this isoleucine residue is critical for TP53 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Database of Curated Mutations (DoCM) RCV000433813 SCV000508702 likely pathogenic Carcinoma of esophagus 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000440110 SCV000508703 likely pathogenic Lung adenocarcinoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000422868 SCV000508704 likely pathogenic Chronic lymphocytic leukemia 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000432689 SCV000508705 likely pathogenic Breast neoplasm 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000441998 SCV000508706 likely pathogenic Neoplasm of brain 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000425285 SCV000508707 likely pathogenic Glioblastoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000432486 SCV000508708 likely pathogenic Pancreatic adenocarcinoma 2016-05-31 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.